BrightGene Bio-Medical Technology updates on share repurchase and investment approval

BrightGene Bio-Medical Technology (SSE:688166) announced the progress of its share repurchase, initiated on September 27, 2025, following a proposal by its controlling shareholder and chairman, Yuan Jiandong. The company has repurchased 55,880 shares, representing 0.0132% of its total share capital, with a total expenditure of CNY 2,993,933.37. The repurchase price ranged from CNY 52.96 to CNY 54.28 per share, and the shares are intended for employee stock ownership plans or equity incentives. No shares were repurchased in November 2025. The repurchase plan has a total value between CNY 10 million and CNY 20 million.

Additionally, at its second extraordinary general meeting on December 1, 2025, BrightGene Bio-Medical Technology’s shareholders approved an external investment and related-party transaction. A total of 398 shareholders, representing 28,606,622 voting rights (11.0109% of total), participated in the vote. The resolution passed with 15,133,189 votes in favor, 137,862 against, and 13,335,571 abstentions. Related-party shareholders, including Yuan Jiandong, abstained from voting on this resolution.